Audacious Medical Grant Oncology 2026
The Audacious Medical Grant (AMG) is a financing tool financed by private donations and legacies received by the FNRS.
It makes it possible to support medical or biomedical research projects that are original, daring and creative but which do not find support in traditional funding channels due to a lack of preliminary data, the absence of previous work or an unusual methodology.
- Category
- Projects, credits, ...
- Profile
-
Postdoc (R2), Permanent research status (R3) and Senior research position (R4)
- Periodicity
- Annual
Financing description
The AMG-ONCO is not a financing instrument dependent on Télévie but the FNRS uses the expertise of its Scientific Commission to carry out the evaluation of submitted projects. There is therefore no notion of accumulation between the AMG-ONCO 2026 call and the Télévie 2026 call.
The call concerns all fields of oncology and all approaches (biomedical research, clinical research, epidemiological research, public health, etc.). The submitted project must allow:
- a better understanding of the mechanisms leading to the development of cancers and/or
- the development of new therapeutic avenues and/or
- an improvement in the prevention or detection of cancers.
The AMG-ONCO 2026 call is open until february 18, 2026.
Mini-guide
Audacious Medical Grant Mini-Guide – Oncology (AMG-ONCO) 2026 EN